Answers are grounded in this paper and cite their sources.
The cross-sectional assessment shows reduced metabolic syndrome risk with risperidone in schizophrenia, suggesting the need for careful monitoring.
Long-term risperidone therapy is associated with a lower MetS risk than olanzapine. Regular metabolic monitoring and adjunctive interventions are recommended for high-risk patients.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: